Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Bookmark and Share
Published: 29 Sep 2014
Views: 2769
Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

At a press conference at ESMO 2014, Prof McArthur presents the results of a phase III trial which found that combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieved greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma.

Read the news story  and watch the interview for more.